Crinetics Pharmaceuticals/CRNX

$45.81

-2.24%
-
1D1W1MYTD1YMAX

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its Paltusotine, an investigational, oral somatostatin receptor type 2 (SST2) agonist, is in Phase 3 clinical development for acromegaly and Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors. It has demonstrated pharmacologic proof-of-concept in a Phase 1 clinical study for CRN04894, an investigational, oral ACTH antagonist, that is in Phase 2 clinical studies for the treatment of congenital adrenal hyperplasia and Cushing's disease. Its drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including other programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes and obesity.

Ticker

CRNX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

R. Scott Struthers

Employees

290

Headquarters

San diego, United States

CRNX Metrics

BasicAdvanced
$3.7B
Market cap
-
P/E ratio
-$3.77
EPS
0.66
Beta
-
Dividend rate
$3.7B
0.65932
$53.70
$15.76
913K
17.718
-35.57%
-40.76%
-37.86%
1,872.015
4.206
4.224
-53.93%
-15.11%
283.77%

What the Analysts think about CRNX

Analyst Ratings

Majority rating from 14 analysts.
Buy

Price Targets

Average projection from 13 analysts.
45.08% upside
High $97.00
Low $48.00
$45.81
Current price
$66.46
Average price target

CRNX Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-11,150% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$600K
∞%
Net income
-$67M
11.5%
Profit margin
-11,150%
-∞%

CRNX Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 14.9%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.94
-$1.01
-$0.90
-$0.93
-
Expected
-$0.86
-$0.86
-$0.86
-$0.81
-$0.86
Surprise
9.61%
17.59%
4.36%
14.9%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Crinetics Pharmaceuticals stock?

Crinetics Pharmaceuticals (CRNX) has a market cap of $3.7B as of May 30, 2024.

What is the P/E ratio for Crinetics Pharmaceuticals stock?

The price to earnings (P/E) ratio for Crinetics Pharmaceuticals (CRNX) stock is 0 as of May 30, 2024.

Does Crinetics Pharmaceuticals stock pay dividends?

No, Crinetics Pharmaceuticals (CRNX) stock does not pay dividends to its shareholders as of May 30, 2024.

When is the next Crinetics Pharmaceuticals dividend payment date?

Crinetics Pharmaceuticals (CRNX) stock does not pay dividends to its shareholders.

What is the beta indicator for Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals (CRNX) has a beta rating of 0.66. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Crinetics Pharmaceuticals stock price target?

The target price for Crinetics Pharmaceuticals (CRNX) stock is $66.46, which is 45.08% above the current price of $45.81. This is an average based on projections from 13 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Crinetics Pharmaceuticals stock

Buy or sell Crinetics Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing